CN117203342A - 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途 - Google Patents

人乳头瘤病毒疫苗及其用于hpv相关疾病的用途 Download PDF

Info

Publication number
CN117203342A
CN117203342A CN202180089584.2A CN202180089584A CN117203342A CN 117203342 A CN117203342 A CN 117203342A CN 202180089584 A CN202180089584 A CN 202180089584A CN 117203342 A CN117203342 A CN 117203342A
Authority
CN
China
Prior art keywords
hpv
protein
polypeptide
polynucleotide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089584.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·E·布拉夫
D·R·埃蒂雷迪
杨琦
王晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presigen Co
Original Assignee
Presigen Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presigen Co filed Critical Presigen Co
Publication of CN117203342A publication Critical patent/CN117203342A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180089584.2A 2020-11-25 2021-11-23 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途 Pending CN117203342A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118222P 2020-11-25 2020-11-25
US63/118,222 2020-11-25
PCT/US2021/060605 WO2022115470A1 (en) 2020-11-25 2021-11-23 Human papilloma virus vaccines and uses of the same for hpv associated diseases

Publications (1)

Publication Number Publication Date
CN117203342A true CN117203342A (zh) 2023-12-08

Family

ID=81754898

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089584.2A Pending CN117203342A (zh) 2020-11-25 2021-11-23 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途

Country Status (10)

Country Link
US (1) US20240173396A1 (https=)
EP (1) EP4251278A4 (https=)
JP (1) JP2023550480A (https=)
KR (1) KR20230113331A (https=)
CN (1) CN117203342A (https=)
AU (1) AU2021385551A1 (https=)
CA (1) CA3197920A1 (https=)
IL (1) IL303113A (https=)
MX (1) MX2023006038A (https=)
WO (1) WO2022115470A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117965634A (zh) * 2024-04-01 2024-05-03 北京唯源立康生物科技股份有限公司 一种新型hsv-1病毒载体及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121752584A (zh) * 2023-05-22 2026-03-27 普瑞赛格恩公司 用于治疗复发性呼吸道乳头状瘤病的新型腺病毒疫苗疗法
EP4716549A2 (en) * 2023-05-22 2026-04-01 Precigen, Inc. T cell receptors generated as a result of hpv vaccine therapy and methods of treating patients with same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ES2276948T3 (es) * 2001-08-23 2007-07-01 MERCK & CO., INC. Ensayos pcr de hp multiplex fluorescente que usan fluoforos multiples.
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
MX360449B (es) * 2011-10-12 2018-11-01 Univ Pennsylvania Vacunas para el virus del papiloma humano y metodos para su uso.
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
KR20250136930A (ko) * 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117965634A (zh) * 2024-04-01 2024-05-03 北京唯源立康生物科技股份有限公司 一种新型hsv-1病毒载体及其应用

Also Published As

Publication number Publication date
MX2023006038A (es) 2023-07-11
AU2021385551A1 (en) 2023-06-22
WO2022115470A1 (en) 2022-06-02
IL303113A (en) 2023-07-01
KR20230113331A (ko) 2023-07-28
CA3197920A1 (en) 2022-06-02
US20240173396A1 (en) 2024-05-30
JP2023550480A (ja) 2023-12-01
EP4251278A4 (en) 2025-09-03
EP4251278A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US20260098063A1 (en) Human papillomavirus vaccines and uses of the same
JP7355399B2 (ja) 子宮頸癌を処置する方法
US20250223320A1 (en) Hepatitis b vaccines and uses of the same
CN117203342A (zh) 人乳头瘤病毒疫苗及其用于hpv相关疾病的用途
RU2850195C1 (ru) Вакцины против вируса папилломы человека и их применение для лечения заболеваний, связанных с hpv
CA3092935C (en) Hepatitis b vaccines and uses of the same
US20240390475A1 (en) Human papillomavirus vaccines and uses of the same
US20240398926A1 (en) Novel adenovirus vaccine therapy for the treatment of recurrent respiratory papillomatosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: American Maryland

Applicant after: Presigen Co.

Address before: Virginia

Applicant before: Presigen Co.

Country or region before: U.S.A.